Insmed has dosed first Cystic Fibrosis (CF) patient in the Clinical Evaluation of ARIKACE (CLEAR-108) phase 3 study of Arikace (liposomal amikacin for inhalation) in Europe. CLEAR-108 is a 300-patient randomized phase 3 trial comparing ...
Tags: Study of Arikace, pulmonary function, open-label safety study